{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:14:33Z","timestamp":1789568073947,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,4]],"date-time":"2027-02-04T00:00:00Z","timestamp":1801699200000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI143256"],"award-info":[{"award-number":["R01 AI143256"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R37 AI034495"],"award-info":[{"award-number":["R37 AI034495"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL118979"],"award-info":[{"award-number":["R01 HL118979"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL154757"],"award-info":[{"award-number":["R01 HL154757"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL155114"],"award-info":[{"award-number":["R01 HL155114"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["R01 CA290808"],"award-info":[{"award-number":["R01 CA290808"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ymthe.2025.11.019","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:53:18Z","timestamp":1763185998000},"page":"898-915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineered suppressor T cells overexpressing IFN-\u03b1 and PD-L1 inhibit GVHD but retain GVL effects in mice"],"prefix":"10.1016","volume":"34","author":[{"given":"Yuanyuan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciril","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-2728","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.11.019_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41571-020-0356-4","article-title":"Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD","volume":"17","author":"Blazar","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib2","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.11.019_bib3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.11.019_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1045168","article-title":"Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease","volume":"13","author":"Doglio","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189676","article-title":"Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges","volume":"22","author":"Hefazi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.11.019_bib6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2019000951","article-title":"Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance","volume":"136","author":"Voermans","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib7","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2017-11-785865","article-title":"Immune regulatory cell infusion for graft-versus-host disease prevention and therapy","volume":"131","author":"Blazar","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib8","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/trf.16797","article-title":"Regulatory T cells: A review of manufacturing and clinical utility","volume":"62","author":"Mamo","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.ymthe.2025.11.019_bib9","first-page":"611.e1","article-title":"A Low Level of Plasmacytoid Dendritic Cells at Engraftment Is a Valuable Prognostic Indicator in Children Receiving Allogeneic Hematopoietic Stem Cell Transplantation","volume":"27","author":"Li","year":"2021","journal-title":"Transpl. Cell. Ther."},{"key":"10.1016\/j.ymthe.2025.11.019_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI136774","article-title":"Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction","volume":"131","author":"Tian","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.11.019_bib11","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2013.54.4577","article-title":"Improved survival after transplantation of more donor plasmacytoid dendritic or naive T cells from unrelated-donor marrow grafts: results from BMTCTN 0201","volume":"32","author":"Waller","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V93.2.728","article-title":"Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation","volume":"93","author":"Fearnley","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1704827","article-title":"Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft-versus-host disease","volume":"35","author":"Vakkila","year":"2005","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.ymthe.2025.11.019_bib14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.11.019_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00281-016-0602-0","article-title":"The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues","volume":"39","author":"Devi","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib16","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.4049\/jimmunol.1601629","article-title":"The Importance of Dendritic Cells in Maintaining Immune Tolerance","volume":"198","author":"Audiger","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nri3477","article-title":"The role of dendritic cells in autoimmunity","volume":"13","author":"Ganguly","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid Dendritic Cells: Development, Regulation, and Function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.11.019_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41590-017-0012-z","article-title":"Diversification of human plasmacytoid predendritic cells in response to a single stimulus","volume":"19","author":"Alculumbre","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells","volume":"23","author":"Sumida","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib21","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.11.019_bib22","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","article-title":"Genetic and Epigenetic Regulation of PD-1 Expression","volume":"196","author":"Bally","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.11.019_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.11.019_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.2023021126","article-title":"Tissue-infiltrating Alloreactive T Cells Require Id3 to Deflect PD-1-mediated Immune Suppression during GVHD","volume":"143","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/JLB.5AB0820-542RR","article-title":"A novel clinically relevant graft-versus-leukemia model in humanized mice","volume":"111","author":"Jia","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib27","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1172\/JCI91138","article-title":"PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells","volume":"127","author":"Ni","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.11.019_bib28","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2010-12-325746","article-title":"Type I-IFNs control GVHD and GVL responses after transplantation","volume":"118","author":"Robb","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib29","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood.2020006345","article-title":"Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity","volume":"137","author":"Song","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4049\/jimmunol.1402157","article-title":"B7H1\/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease","volume":"194","author":"Deng","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib31","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2007-12-127449","article-title":"Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1\/PD-L1 pathway","volume":"112","author":"Haspot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4049\/jimmunol.1102630","article-title":"Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease","volume":"188","author":"Li","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib33","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood-2011-10-387977","article-title":"Contrasting acute graft-versus-host disease effects of Tim-3\/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells","volume":"120","author":"Veenstra","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib35","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.019_bib36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","article-title":"Tim-3 Expression on Tumor-Infiltrating PD-1(+)CD8(+) T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma","volume":"77","author":"Granier","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.11.019_bib37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/bmj.294.6577.919","article-title":"Drug formularies in hospitals","volume":"294","author":"Petrie","year":"1987","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ymthe.2025.11.019_bib38","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.174.8.4465","article-title":"Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation","volume":"174","author":"Curtsinger","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib39","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1084\/jem.155.6.1610","article-title":"Interferon inhibits the generation of allospecific suppressor T lymphocytes","volume":"155","author":"Fradelizi","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.11.019_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2019.01.013","article-title":"The role of type I interferons in CD4(+) T cell differentiation","volume":"215","author":"Kuka","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2025.11.019_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.11.019_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev-immunol-032712-095956","article-title":"Metabolic regulation of T lymphocytes","volume":"31","author":"MacIver","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2025.11.019_bib45","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.019_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf. Open Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib47","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.immuni.2023.01.003","article-title":"Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells","volume":"56","author":"Sacirbegovic","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.11.019_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184332","article-title":"Calcineurin inhibitor blocks tolerance by suppressing donor T cell terminal exhaustion after allogeneic hematopoietic cell transplantation","volume":"134","author":"Senjo","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.11.019_bib51","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2004-12-4726","article-title":"Leukocyte migration and graft-versus-host disease","volume":"105","author":"Wysocki","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1201248","article-title":"Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease","volume":"367","author":"Reshef","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.11.019_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","article-title":"CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies","volume":"13","author":"Jakharia","year":"2021","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.11.019_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.ymthe.2025.11.019_bib55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib56","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.4049\/jimmunol.176.7.4284","article-title":"IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections","volume":"176","author":"Bahl","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fcimb.2013.00077","article-title":"Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection","volume":"3","author":"Malireddi","year":"2013","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/ol.2022.13355","article-title":"Interferon-alpha and its effects on cancer cell apoptosis","volume":"24","author":"Shi","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ymthe.2025.11.019_bib59","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/bloodadvances.2019000453","article-title":"Pegylated interferon-2alpha invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation","volume":"3","author":"Henden","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.11.019_bib60","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1182\/bloodadvances.2021004908","article-title":"Type 1 interferon to prevent leukemia relapse after allogeneic transplantation","volume":"5","author":"Magenau","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.11.019_bib61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","article-title":"Regulation of effector and memory T-cell functions by type I interferon","volume":"132","author":"Huber","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2025.11.019_bib62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.11.019_bib63","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2013-05-505180","article-title":"The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T cell responses mediating graft-versus-host disease","volume":"122","author":"He","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib64","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood-2016-08-735886","article-title":"Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice","volume":"129","author":"Huang","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib65","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1172\/JCI39692","article-title":"PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice","volume":"119","author":"Valenzuela","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.11.019_bib66","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.4049\/jimmunol.1202820","article-title":"Delta-like Ligand 4 Identifies a Previously Uncharacterized Population of Inflammatory Dendritic Cells That Plays Important Roles in Eliciting Allogeneic T Cell Responses in Mice","volume":"190","author":"Mochizuki","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib67","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1182\/blood-2015-05-644476","article-title":"Programming of donor T cells using allogeneic delta-like ligand 4-positive dendritic cells to reduce GVHD in mice","volume":"127","author":"Mochizuki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.11.019_bib68","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.4049\/jimmunol.174.5.3051","article-title":"Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease","volume":"174","author":"Zhang","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.11.019_bib69","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.2021014557","article-title":"BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes","volume":"139","author":"Zaiken","year":"2022","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625009566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625009566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:34:14Z","timestamp":1770222854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625009566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1525001625009566"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.11.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered suppressor T cells overexpressing IFN-\u03b1 and PD-L1 inhibit GVHD but retain GVL effects in mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}